Jan Skvarka - 16 Jun 2023 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role: Director
Signature: /s/ Melissa B. Epperly, Attorney-in-Fact for Jan Skvarka
Issuer symbol: ZNTL
Transactions as of: 16 Jun 2023
Net transactions value: $0
Form type: 4
Filing time: 16 Jun 2023, 17:01:25 UTC
Previous filing: 15 Jun 2023
Next filing: 13 Sep 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ZNTL	Common Stock	Award	$0	+16,364	+45%	$0.000000	52,970	16 Jun 2023	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2024 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.

Content

Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2024 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.